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Abstract
Background: Leprosy is a chronic granulomatous infectious disease and is still endemic in many parts of the world. It causes
disabilities which are the consequence of nerve damage. This damage is in most cases the result of immunological
reactions.
Objectives: To investigate the differences between a type 1 leprosy (reversal) reaction and relapse on using histopathology.
Methods: The histopathological changes in 167 biopsies from 66 leprosy patients were studied. The patients were selected
when their sequential biopsies demonstrated either different patterns or maintained the same pattern of granulomatous
reaction over more than two years during or after the treatment of leprosy.
Results: In 57 of the patients studied, a reactivation was seen which coincided with a decrease in the bacteriological index
(BI), suggesting that this reactivation (reversal reaction or type 1 leprosy reaction) coincides with an effective capacity for
bacteriological clearance. In nine patients, an increase of the bacteriologic index (IB) or persistence of solid bacilli occurred
during the reactivation, indicating proliferative activity, suggestive of a relapse. The histopathological aspects of the
granulomas were similar in both groups.
Conclusion: Bacterioscopy provided the only means to differentiate a reversal reaction from a relapse in patients with
granulomatous reactivation. The type 1 leprosy reaction may be considered as a part effective immune reconstitution
(reversal, upgrading reaction) or as a mere hypersensitivity reaction (downgrading reaction) in a relapse.
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Introduction
Leprosy is a chronic infectious disease caused by Mycobacterium
leprae and is still endemic in many parts of the world. Circa 250 000
new cases were reported in 2009 [1]. It affects nerves and skin, may
cause deformities and may evolve with acute exacerbations. The
disease is the result of a granulomatous reaction to bacilli living
inside phagocytes; the host therefore depends on cell mediated
immunity for bacterial elimination. This response varies in different
hosts and therefore gives rise to a clinical spectrum. Two clinical,
histopathological and bacteriological stable poles are defined within
the spectrum. The pole with high cell mediated immune reactivity
to the bacillus is the tuberculoid (TT) pole while the opposite pole
with a predominant humoral immune response is the lepromatous
(LL) pole. Between these poles, intermediate forms are found; these
are immunologically unstable and are called borderline (B):
borderline-tuberculoid (BT), borderline-borderline (BB) and bor-
derline-lepromatous (BL) leprosy [2]. A form that can’t yet be
classified is the indeterminate form (I) [3].
Borderline patients have partial resistance to the bacillus and
during the natural course of the disease some bacilli may multiply
and induce morphological changes in the granulomatous response.
In these cases the granulomas become less compact due to the
presence of oedema, with fewer, more dispersed epithelioid cells
and infiltrating histiocytes. Jopling referred to this as a downgrad-
ing reaction (BB to BL); it was previously described by de Souza,
when no treatment was available [4], [5]. It may also occur in
borderline patients with irregular treatment or drug resistance,
who then move in the leprosy spectrum to the lepromatous pole.
The inhibition of the cellular immune response could be due to
cell wall antigens such as phenolic glycolipid and/or lipoarabino-
manam released by proliferating bacilli [6], [7]. Patients with this
evolution (BL to LL) have been classified by Ridley as having the
sub-polar lepromatous leprosy (LLsp) [8]. As M leprae has a very
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least 3 to 7 years, the disease may develop with discrete symptoms;
the diagnosis is delayed until clinical manifestations of the
downgrading appear. With specific treatment, the bacilli are
destroyed and fragmented. However, clearance of the antigens
and resolution of the skin lesions occur at a rate that depends
largely on the immune resistance of the patient [4], [8], [9].
In this regard, there are borderline patients who during
treatment show a clinical reactivation of old lesions or develop
new skin lesions with erythema and oedema, suggestive of an
upgrading reaction. These lesions tend to regress after a few weeks
or months, sometimes even without treatment. However, in many
cases biopsies of these lesions still show fragmented bacilli inside
nerves, vessels or erector pill muscles or in vacuoles of activated
macrophages, which suggests that a downgrading process took
place before the upgrading reaction and shift to the tuberculoid
pole [9]. The mechanisms underlying such reactions are not clear;
it appears that the presence of dead and fragmented bacilli would
lead to an improvement of the cell mediated immune response.
Although they have originally been described in patients under
treatment, they may also occur before or after the treatment,
suggesting that they belong to the normal course of a leprosy
infection [4], [8], [9], [10].
For better understanding the histopathology of these reactions,
effort was made to classify the acute granulomatous tuberculoid
reaction found in lesional biopsies of leprosy patients as either a
reversal reaction (type 1 reaction or upgrading) or a relapse (with
downgrading). We thus hypothesized that a relapse would be
defined when the granulomatous reaction was accompanied by an
increase or persistence in the bacilloscopy index (BI). On the other
hand, a reversal reaction would be defined when the granuloma-
tous reaction was accompanied either by a fast decrease in the BI.
For this purpose we analyzed the histopathological changes in
patients who show a granulomatous reactivation during or after
treatment. Patients with suspected histopathologically reversal
reaction and relapse are included, in order to examine the
differences between these two states. Relapse has become rare
after the introduction of MDT (multidrug-therapy); therefore this
study analyzes patients registered between 1987 and 1994, when
MDT in Brazil was restricted to a research institution [11].
Materials and Methods
In this study the leprosy patients included presented with at least
one histopathological examination indicating reactivation, deter-
mined either by a tuberculoid granulomatous infiltration with a
change of classification or by a granulomatous infiltration that
persisted for more than two years either during or after treatment.
All biopsies were analyzed at the Lauro of Souza Lima Institute
(ILSL), SES-SP, Brazil, between 1987 and 1994. Data concerning
clinical history were obtained from patients’ records from the
different centers: 26 from ILSL (Bauru-SP), 16 from the State
Institute for Sanitary Dermatology (Curupaiti, RJ) and 24 from the
State Center of Dermatology (Rondono ´polis, MT). All three sites
were referral centers for leprosy patients and followed the
guidelines of the Brazilian Program of Leprosy. A total of 179
histopathological examinations from 66 patients were studied: all
patients were more than 18 years old, 39 were male, 27 were
female. The biopsies were done at the initiation of the treatment
and whenever the clinicians suspected of a reaction, which was
clinically defined by worsening of the previous lesions or
identifying new lesions. Twelve biopsies were excluded because
they showed a non-specific inflammatory reaction or no bacilli. All
biopsies were identified with a code and processed and analyzed at
one center (ILSL, Bauru) by the same pathologists (RNF and
MABT), who were not aware of the clinical data at that moment.
The Committee for Ethical Research of the Escola Paulista de
Medicina, Universidade Federal de Sa ˜o Paulo approved this study.
Informed consent was not necessary because the study was
retrospective and no personal identifiers were used.
The Ridley & Jopling histopathological classification was used
[2]. The method used for BI determination was counting the
bacilli per field according to the criteria established by Ridley &
Hilson (1967) [12], using Fite-Faraco staining. This was done in oil
immersion, 6006magnification, by examining 25–100 fields, and
using a logarithmic scale to score the numbers of bacilli, ranging
from 0 to 6. All slides were also stained with haematoxylin-eosin
(HE) for histopathology analysis. Granulomatous reactions
demonstrating signs of acute inflammation (congestion, oedema,
deposit of fibrin, etc.) were classified as Rc (reactional) [8]. Patients
with an initial histopathological classification of LL whose later
biopsies demonstrated a borderline histopathological picture, were
reclassified as LLsp. Patients who histopathologically moved from
a TT pattern to BT pattern were then classified as BT. Since a
single biopsy may not be sufficient to classify a patient, the
definitive classification took the clinical changes through time into
account. The TT pole is stable; it is not expected to show any
change in clinical, histopathological, and bacteriological exami-
nations. BT patients showed a higher number of skin and nerve
lesions than TT patients and the bacterioscopy was usually
positive. The bacterioscopy was graded using Ridley’s morpho-
logical (MI) and bacteriological (BI) indices [12].
Results
In table 1 the histological patterns of the 66 patients who
showed granulomatous reactivation during or after the treatment
of leprosy, are recorded, grouped by the diagnosis made at first
biopsy: (a) 12 patients were classified as Indeterminate (I); in 11 the
histopathology changed to TT or BTRc, only one changed to BB;
(b) of the 9 patients classified TT and TRc, 5 continued to be TT,
2 TRc became TT and 2 TT became TRc; (c) of the 17 BT and
BTRc patients, 15 remained as BT or BTRc and 2 BT moved
down to BB; (d) all 10 patients classified as BB and BBRc became
BT or BTRc; (e) of the 10 BL and 8 LLsp patients, 7 BL became
Author Summary
Leprosy is a serious infectious disease whose treatment
still poses some challenges. Patients are usually treated
with a combination of antimicrobial drugs called multidrug
therapy. Although this treatment is effective against
Mycobacterium leprae, the bacillus that causes leprosy,
patients may develop severe inflammatory reactions
during treatment. These reactions may be either attributed
to an improvement in the immunological reactivity of the
patient along with the treatment, or to relapse of the
disease due to the proliferation of remaining bacilli. In
certain patients these two conditions may be difficult to
differentiate. The present study addresses the histopathol-
ogy picture of and the M. leprae bacilli in sequential
biopsies taken from lesions of patients who presented
such reactions aiming to improve the differentiation of the
two conditions. This is important because these reactions
are one of the major causes of the disabilities of the
patients with leprosy, and should be treated early and
appropriately. Our results show that the histopathology
picture alone is not sufficient, and that bacilli’s counting is
necessary.
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or BBRc and 4 LLsp became BT or BTRc.
In table 2 the BI of the 66 patients are shown according to the
results of the first biopsy: (a) of the 9 patients with a negative BI on
the first biopsy, 6 showed a positive BI between 1+ and 4+ on the
biopsy taken at the time of reactivation; (b) of the 13 patients with a
BIof 1+ onthefirstbiopsy, 7 showeda BI between 1+ and5+ onthe
reactivation biopsy;(c)ofthe18patients with a BIof2+ or3+ onthe
first biopsy, 7 showed a BI of 1+ or 2+ on reactivation; (d) of the 26
patients with a BI of 4+,5 + or 6+ on the first biopsy, 25 showed a BI
of 1+ to 5+ on reactivation. Of the other 21 patients, 18 moved to
bacterioscopy negative and 3 remained bacterioscopy negative.
Of the 31 patients who had a histopathology showing features of
an acute inflammation (Rc), 9 were patients without treatment
while 22 patients were on or had already finished treatment; in all
cases, the patients had histological patterns ranging from TRc to
BBRc, predominating those with BTRc (data not shown).
When the patients were analyzeda c c o r d i n gt ot h et r e a t m e n t
modality, 9 patients who were treated with dapsone or another
monotherapy, but none of the 57 patients who received the WHO
MDT regimen, showed an increase in or persistence of their bacilli or
the bacterioscopy became positive during the reaction (data not shown).
Discussion
This study analyzes the histopathological changes of a subset of
leprosy patients who showed either a different histopathological
pattern on subsequent biopsies or maintained the same pattern of
granulomatous infiltration for two years or longer, during or after the
treatment of leprosy. They were considered to have a granulomatous
reactivation, which includes both reversal reactions and relapses.
The patients who were classified as indeterminate (I) on the first
biopsy developed granulomatous reactions that were classified as
TT or BT. This occurred regardless of the treatment regimen, with
the exception of one patient whose initial biopsy showed a positive
bacterioscopy with a very mild inflammatory infiltrate, who
subsequently developed BB- leprosy. This suggests that in the more
resistant individuals treatment does not necessarily modify the
natural course of the disease. Alternatively it may be suggested that
the bacteriostatic/cidal action of the drugs would lead to bacilli
fragmentation and enhanced antigen exposure, which in turn
induced a granulomatous reaction. Analysis of the patients that
presented with histopathological acute reactional patterns during
treatment showed that the granulomatous reactivations occurred
earlier and more frequently among those who had received
rifampicin. This is probably a consequence of the rapid bactericidal
activity of the drug [13]. This granulomatous reactional (Rc) aspect
was also found, albeit less frequently, in the initial biopsy of some
patients before treatment; in these cases it was considered to be the
result of changes in the immune status of the patients, due to as yet
unknown host factors [4], [8], [14], [15].
Table 1. Evolution of histological patterns from 66 leprosy
patients presented reactivation during or after treatment.
1
st biopsy* 2
nd biopsy 3
rd biopsy 4
th biopsy
? patients (?
with relapse**)
I IT T - 1
TT - - 5
TT TRc - 2
BT BT - 1
BT BT BT 1 (1)
BTRc BT - 1
BB - - 1 (1)
Sub total 12
TT TT - - 5
TRc - - 1
TRc TT - 1
Sub total 7
TRc TT - - 2
Sub total 2
BT BT - - 2 (2)
BT BT - 3
BTRc - - 3 (1)
BTRc BT - 2 (2)
BB - - 2 (1)
Sub total 12
BTRc BT - - 1
BT BTRc - 1
BT BTRc BT 1
BTRc BTRc BTRc 2
Sub total 5
BB BT - - 4
BTRc - - 2
BB BT - 2
Sub total 8
BBRc BTRc BTRc - 1
BB BT BT 1
Sub total 2
BL BT - - 1
BT BTRc - 1
BTRc - - 1
BTRc BT - 1
BTRc BTRc - 2
BB - - 1
BBRc BTRc - 1
BBRc BB BB 1
BBRc BBRc - 1 (1)
Sub total 10
LLsp BT - - 2
BB - - 3
BB BT - 1
BBRc BTRc - 1
BBRc - - 1
Sub total 8
1
st biopsy* 2
nd biopsy 3
rd biopsy 4
th biopsy
? patients (?
with relapse**)
TOTAL 66
*Patients were grouped according to the pattern of the first biopsy.
**In parentheses are the 9 cases with relapse. (I) Indeterminate, (TT)
tuberculoid-torpid, (TRc) tuberculoid-reactional, (BT) borderline-tuberculoid,
(BTRc) borderline-tuberculoid-reactional, (BB) borderline-borderline, (BBRc)
borderline-borderline-reactional, (BL) borderline-lepromatosus, (LLsp)
lepromatous- subpolar, (-) biopsy not done.
doi:10.1371/journal.pntd.0000921.t001
Table 1. Cont.
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subsequently showed different histopathological patterns. During
the reactivation resulting in granulomatous infiltrations, in some
patients the patterns moved towards the tuberculoid pole of the
leprosy spectrum, thus presenting an upgrading or reversal reaction.
This was more evident in patients initially classified as subpolar
lepromatous or borderline lepromatous. Patients with these changes
may have gone through a downgrading before treatment, as
previously suggested [16]. These reactivations do not necessarily
represent a return to the initial situation, because only two
histopathological patterns of reactivation were observed (BT and
BB); there was no granulomatous reactivation with a BL pattern.
At the tuberculoid pole, some patients showed a reversal
reaction while maintaining the same histological presentation,
especially the patients classified as BTRc. This was previously
reported by Souza Lima & Souza Campos, before the advent of
sulphone treatment [5]. Following the start of dapsone treatment it
was reported by Opromolla, who suggested that it was caused by
episodes of bacterial proliferation (presumably of persisting
bacteria) in resistant individuals [17].
In the majority of the patients studied, the episodes of
granulomatous reactivation coincided with a decrease in the
bacteriological index, suggesting that this reactivation occurs
parallel to an effective capacity for bacterial clearance. In contrast,
in nine patients there was an increase in the BI during the
reactivation episodes ($2+ relative to the previous BI) or
appearance or continuous presence of solid bacilli, indicating
bacilli replication [18–20]. These reactivations are considered to
represent a relapse or a downgrading reaction, probably due to
bacteriological resistance or inadequate treatment. These patients
had all been treated previously with a single drug regimen; in two
of these patients, a change to a MDT regimen resulted in effective
reduction in BI in the reactivations/reactions biopsy.
In general the reversal reactions showed a more intense
histopathological pattern: more granulomatous with a clearer
tuberculoid aspect, more epitheloid cells, usually more grouped
than before treatment, suggesting that an active immune
reconstitution is taking place. This has been demonstrated in
studies showing a more tuberculoid pattern with signs of increased
immunological activity with a Th1 response in skin and/or nerves
in patients with a reversal or type 1 leprosy reaction when those
patients were compared with patients clinically not in reaction.
These studies showed enhanced in situ staining for TNF and other
pro-inflammatory cytokines such as IFN-c and IL-12 and for the
enzyme nitric oxide synthase in reactional lesions [21], [22].
The same pattern of histopathological changes occurs in
patients with AIDS coinfected with M. leprae when they start on
highly active antiretroviral therapy (HAART). This is considered
Table 2. Evolution of the bacilloscopy index from 66 leprosy
patients presented reactivation during or after treatment.
1
st biopsy* 2
nd biopsy 3
rd biopsy 4
th biopsy
? patients (?
with relapse)**
Negative BI neg --2
neg neg -1
1 neg -2
2-- 1 (1)
2 neg -1
22neg 1 (1)
41- 1 (1)
Subtotal 9
BI 1+ neg --6
1-- 2
1 neg -1
4-- 1 (1)
43- 1 (1)
5-- 2 (2)
Subtotal 13
BI 2+ neg --4
neg neg -1
neg neg neg 1
1-- 2
22- 1
Subtotal 9
BI 3+ neg --4
neg neg -1
neg 111
1-- 1
1 neg -1
22neg 1
Subtotal 9
BI 4+ neg 3- 1
1-- 1
11- 3
11neg 1
21- 1
3-- 2
31- 1
4-- 1 (1)
41- 1
Subtotal 12
BI 5+ neg --1
2-- 1
2 neg -2
21- 1
3-- 1
4-- 2
41- 1
41neg 1
Subtotal 10
BI 6+ 4-- 2
Table 2. Cont.
1
st biopsy* 2
nd biopsy 3
rd biopsy 4
th biopsy
? patients (?
with relapse)**
44 1 (1)
5- 1
Subtotal 4
Total 66
*Patients were grouped according to the pattern of first biopsy and in
parenthesis are the 9 relapse cases.
**In parentheses are the 9 cases with relapse. Positive BI: bacilloscopy index
in+(1 to 6); neg: biopsy with absence of bacilli; -: biopsy not done.
doi:10.1371/journal.pntd.0000921.t002
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occurs in some coinfected patients, in whom, due to the AIDS-
associated cellular immunesuppression, leprosy remains a latent
infection and clinically manifests as type 1 reaction after immune
restoration is induced with HAART [23–29]. The reactions that
appear after the start of leprosy treatment, specially MDT, may
represent a similar immune restoration phenomenon [13], [14],
[30]. In these cases the bacilli are destroyed by the granulomatous
reactivation during the reactional episodes (reversal or type 1
reaction). This is illustrated in the present study by the 57 patients
who where on MDT (or in a few cases with an alternative
treatment containing rifampicine, the only mycobactericidal drug)
and evolved with granulomatous reactional episodes and decrease
in the BI [30], [31].
In patients on MDT, episodes of bacillary proliferation of
persistent bacilli would be rare and possibly controlled by a similar
granulomatous reaction. However, occasionally an increased
bacillary load or decreased immune resistance may occur and
resemble a relapse. This was observed in patients who had received
sulphone mono-therapy exclusively over a long period of time. In
these patients, persistent bacilli and/ordrug-resistancemay give rise
to a new episode of bacillary proliferation during or after the
treatment; subsequently the host fosters a new granulomatous
reaction in a relapse. The granulomatous histopathology of relapses
studied here were not different from the histopathology of
downgrading type I reactions described by Jopling [4].
Our hypothesis is that the granulomatous reactivations, both the
up- and downgrading reactions, can be triggered by live bacilli
that multiply. However, in upgrading reaction the granulomatous
immune response is effective, leading to destruction of the bacilli
and reduction of the BI. In the downgrading reaction, the
granulomatous reaction is not as efficient in the control of bacilli
multiplication and an increase in the BI can be more easily
detected. Thus, the histopathological patterns of granulomatous
reactivations are similar and differentiation between reversal and
relapses type 1 reactions, are only possible when an increase in BI
is seen.
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